vTv Therapeutics 

$36.56
24
-$0.74-1.98% Friday 20:00

Statistics

Day High
38.1
Day Low
35.04
52W High
44
52W Low
14
Volume
38,444
Avg. Volume
44,291
Mkt Cap
143.97M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-3.6
-2.42
-1.23
-0.04
Expected EPS
-0.045
Actual EPS
N/A

Financials

-1,815.34%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
2.03MRevenue
-36.92MNet Income

Analyst Ratings

$53.00Average Price Target
The highest estimate is 67.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VTVT. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap26.03B
Biogen has a strong portfolio in neurodegenerative diseases, including Alzheimer's, making it a direct competitor to vTv Therapeutics.
Axsome Therapeutics
AXSM
Mkt Cap8.62B
Axsome Therapeutics works on central nervous system disorders, including Alzheimer's disease, competing in the same space as vTv Therapeutics.
AnaptysBio
ANAB
Mkt Cap1.66B
AnaptysBio is involved in developing therapeutic antibodies for inflammatory diseases, which could overlap with vTv Therapeutics' work on conditions like psoriasis.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.78B
ACADIA Pharmaceuticals focuses on central nervous system disorders, posing competition to vTv Therapeutics' Alzheimer's disease treatments.
Alkermes
ALKS
Mkt Cap5.81B
Alkermes works on central nervous system diseases, including treatments for schizophrenia and bipolar I disorder, areas that could compete with vTv Therapeutics' focus.
AMGEN
AMGN
Mkt Cap187.56B
Amgen's broad focus on innovative therapeutics includes work on neurodegenerative diseases, making it a competitor in the Alzheimer's space.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie has a diverse portfolio that includes neuroscience, directly competing with vTv Therapeutics in the Alzheimer's and cognitive impairment market.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly has a strong presence in Alzheimer's disease research and treatment, directly competing with vTv Therapeutics.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a wide range of therapeutic areas, including Alzheimer's disease research, making it a competitor to vTv Therapeutics.

About

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Show more...
CEO
Mr. Paul J. Sekhri
Employees
23
Country
US
ISIN
US9183852048

Listings

0 Comments

Share your thoughts

FAQ

What is vTv Therapeutics stock price today?
The current price of VTVT is $36.56 USD — it has decreased by -1.98% in the past 24 hours. Watch vTv Therapeutics stock price performance more closely on the chart.
What is vTv Therapeutics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange vTv Therapeutics stocks are traded under the ticker VTVT.
Is vTv Therapeutics stock price growing?
VTVT stock has fallen by -11.2% compared to the previous week, the month change is a +4.16% rise, over the last year vTv Therapeutics has showed a +94.78% increase.
What is vTv Therapeutics market cap?
Today vTv Therapeutics has the market capitalization of 143.97M
When is the next vTv Therapeutics earnings date?
vTv Therapeutics is going to release the next earnings report on May 07, 2026.
What were vTv Therapeutics earnings last quarter?
VTVT earnings for the last quarter are -0.58 USD per share, whereas the estimation was -1.09 USD resulting in a +46.69% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is vTv Therapeutics revenue for the last year?
vTv Therapeutics revenue for the last year amounts to 2.03M USD.
What is vTv Therapeutics net income for the last year?
VTVT net income for the last year is -36.92M USD.
How many employees does vTv Therapeutics have?
As of April 11, 2026, the company has 23 employees.
In which sector is vTv Therapeutics located?
vTv Therapeutics operates in the Health Care sector.
When did vTv Therapeutics complete a stock split?
The last stock split for vTv Therapeutics was on November 21, 2023 with a ratio of 1:40.
Where is vTv Therapeutics headquartered?
vTv Therapeutics is headquartered in High Point, US.